Novel therapeutic usage of low-dose doxepin hydrochloride

• ROTH T, ZORICK F, WITTIG R, McLENAGHAN A, ROEHRS T: The effects of doxepin HCl on sleep and depression. J. Clin. Psychiatry (1982) 43:366-368.
   PubMed Web of Science ®Google Scholar
• AYD FJ Jr: Long-term treatment of chronic depression: 15-year experience with doxepin HCl. J. Clin. Psychiatry (1984) 45:39-46.
   PubMed Web of Science ®Google Scholar
• SMALL GW: Antidepressants for medically ill geriatric patients. J. Clin. Psychiatry (1989) 50(Suppl.):27-31.
   PubMedGoogle Scholar
• LAKSHMANAN M, MION LC, FRENGLEY JD: Effective low dose tricyclic antidepressant treatment for depressed geriatric rehabilitation patients. A double-blind study. J. Am. Geriatric Soc. (1986) 34:421-426.
   PubMed Web of Science ®Google Scholar
• JARVIK LF, MINTZ J, STEUER J, GERNER R: Treating geriatric depression: a 26-week interim analysis. J. Am. Geriatric Soc. (1982) 30:713-717.
   PubMed Web of Science ®Google Scholar
• STAFFORD RS, MACDONALD EA, FINKLESTEIN SN: National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J. Clin. Psychiatry (2001) 3:232-235.
   PubMedGoogle Scholar
• SZEWCZUK-BOGUSLAWSKA M, KIEJNA A, BESZLEJ JA, ORZECHOWSKA-JUZWENKO K, MILEJSKI P: Doxepin inhibits CYP2D6 activity in vivo. Pol. J. Pharmacol. (2004) 56:491-494.
   PubMedGoogle Scholar
• ERESHEFSKY L, TRAN-JOHNSON T, DAVIS CM, LEROY A: Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine-new data and review. Clin. Chem. (1988) 34:863-880.
   PubMed Web of Science ®Google Scholar
• MEYER-BARNER M, MEINEKE I, SCHREEB KH, GLEITER CH:Pharmacokinetics of doxepin and desmethyldoxepin: an evaluation with the population approach. Eur. J. Clin. Pharmacol. (2002) 58:253-257.
   PubMed Web of Science ®Google Scholar
• PECKNOLD JC, LUTHE L: Trimipramine, anxiety, depression and sleep. Drugs (1989) 38(Suppl. 1):25-31.
   PubMed Web of Science ®Google Scholar
• RIEMANN D, VODERHOLZER U, COHRS S et al.: Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry (2002) 35:165-174.
   PubMed Web of Science ®Google Scholar
• SMITH JA, RENSHAW DC: A clinical study of insomnia. Am. Fam. Physician (1975) 3:140-141.
   Google Scholar
• HAJAK G, RODENBECK A, ADLER L et al.: Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry (1996) 29:187-192.
   PubMed Web of Science ®Google Scholar
• RODENBECK A, HAJAK G, HUETHER G: Melatonin in insomniac patients and effects of sleep medication. Adv. Exp. Med. Biol. (1996) 398:113-117.
   PubMedGoogle Scholar
• RODENBECK A, HUETHER G, RUTHER E, HAJAK G: Nocturnal melatonin secretion and its modification by treatment in patients with sleep disorders. Adv. Exp. Med. Biol. (1999) 467:89-93.
   PubMed Web of Science ®Google Scholar
• HAJAK G, RODENBECK A, VODERHOLZER U et al.: Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J. Clin. Psychiatry (2001) 62:453-463.
   PubMed Web of Science ®Google Scholar
• RODENBECK A, HAJAK G: Neuroendocrine dysregulation in primary insomnia. Rev. Neurol. (Paris) (2001) 157:S57-S61.
   PubMed Web of Science ®Google Scholar
• RODENBECK A, COHRS S, JORDAN W, HUETHER G, RUTHER E, HAJAK G: The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (2003) 170:423-428.
   PubMed Web of Science ®Google Scholar
• DURRENCE H: Phase I data summarized and provided by Senior Manager for Publication Planning and Professional Communication at Somaxon Pharmaceuticals, Inc. (2007).
   Google Scholar
• ROTH T, ROGOWSKI R, HULL S et al.: Efficacy and safety of doxepin 1, 3, and 6 mg in adults with primary insomnia. Sleep (2007) Submitted.
   Google Scholar
• SCHARF M, ROGOWSKI R, HULL S et al.: Efficacy and safety of doxepin 1, 3 and 6 mg in elderly patients with primary insomnia. J. Am. Geriatric Society (2007) Submitted.
   Google Scholar
• BROWNELL LG, WEST P, SWEATMAN P, ACRES JC, KRYGER MH: Protriptyline in obstructive sleep apnea: a double-blind trial. N. Engl. J. Med. (1982) 307:1037-1042.
   PubMed Web of Science ®Google Scholar
• SMITH PL, HAPONIK EF, ALLEN RP, BLEECKER ER: The effects of protriptyline in sleep-disordered breathing. Am. Rev. Respir. Dis. (1983) 127:8-13.
   PubMed Web of Science ®Google Scholar
• GRUNSTEIN RR, HEDNER J, GROTE L: Treatment options for sleep apnoea. Drugs (2003) 61:237-251.
   Web of Science ®Google Scholar
• RUBIN AH, ALROY GG, PELED R, LAVIE P: Preliminary clinical experience with imipramine HCl in the treatment of sleep apnea syndrome. Eur. Neurol. (1986) 25:81-85.
   PubMed Web of Science ®Google Scholar
• BECKER PM: Mild sleep disordered breathing (SDB): better management by protriptyline and doxepin. Sleep (2003) 26:A250 (Abstract Supplement).
   PubMed Web of Science ®Google Scholar
• VEASEY SC, GUILLEMINAULT C, STROHL KP, SNADERS MH, BALLARD RD, MAGALANG UJ: Medical therapy for obstructive sleep apnea: a review by the medical therapy for obstructive sleep apnea task force of the standards of practice committee of the American academy of sleep medicine. Sleep (2006) 29:1036-1044.
   PubMed Web of Science ®Google Scholar
• SUDOH Y, CAHOON EE, GERNER P, WANG GK: Tricyclic antidepressants as long-acting local anesthetics. Pain (2003) 103:49-55.
   PubMed Web of Science ®Google Scholar
• RICHEIMER SH, BAJWA ZH, KAHRAMAN SS, RANSIL BJ, WARFIELD CA: Utilization patterns of tricyclic antidepressants in a multidisciplinary pain clinic: a survey. Clin. J. Pain (1997) 13:324-329.
   PubMed Web of Science ®Google Scholar
• MCCLEANE G: Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br. J. Clin. Pharmacol. (2000) 49:574-579.
   PubMed Web of Science ®Google Scholar
• BERBERIAN BJ, BRENEMAN DL, DRAKE LA et al.: The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis. Int. J. Dermatol. (1999) 38:145-148.
   PubMed Web of Science ®Google Scholar
• AHLES S, GWIRTSMAN H, HALARIS A, SHAH P, SCHWARZ G, HILL MA: Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. J. Clin. Psychiatry (1984) 45:460-465.
   PubMed Web of Science ®Google Scholar
• HAMEROFF SR, WEISS JL, LERMAN JC et al.: Doxepin's effects on chronic pain and depression: a controlled study. J. Clin. Psychiatry (1984) 45:47-53.
   PubMed Web of Science ®Google Scholar
• HAMEROFF SR, CORK RC, SCHERER K et al.: Doxepin effects on chronic pain, depression and plasma opioids. J. Clin. Psychiatry (1982) 43:22-27.
   PubMed Web of Science ®Google Scholar
• DAVIS MP, SRIVASTAVA M: Demographics, assessment and management of pain in the elderly. Drugs Aging (2003) 20:23-57.
   PubMed Web of Science ®Google Scholar
• MCCLEANE G: Topical application of doxepin hydrochloride can reduce the symptoms of complex regional pain syndrome: a case report. Injury (2002) 33:88-89.
   PubMed Web of Science ®Google Scholar
• SANDROCK NJ, WARFIELD CA: Managing the pain of herpes zoster. Hosp. Pract. (Off Ed.) (1986) 30:81, 84-86, 92-93.
   Google Scholar
• WARD N, BOKAN JA, PHILLIPS M, BENEDETTI C, BUTLER S, SPENGLER D: Antidepressants in concomitant chronic back pain and depression: doxepin and desipramine compared. J. Clin. Psychiatry (1984) 45:54-59.
   PubMed Web of Science ®Google Scholar
• PUNAY NC, COUCH JR: Antidepressants in the treatment of migraine headache. Curr. Pain Headache Rep. (2003) 7:51-54.
   PubMedGoogle Scholar
• ADELMAN JU, VON SEGGERN R: Cost considerations in headache treatment. Part 1: prophylactic migraine treatment. Headache (1995) 35:479-487.
   PubMed Web of Science ®Google Scholar
• SJAASTAD O: So-called ‘tension headache’ – the response to a 5-HT uptake inhibitor: femoxetine. Cephalalgia (1983) 3:53-60.
   PubMed Web of Science ®Google Scholar
• MORLAND TJ, STORLI OV, MOGSTAD TE: Doxepin in the prophylactic treatment of mixed ‘vascular’ and tension headache. Headache (1979) 19:382-383.
   PubMed Web of Science ®Google Scholar
• WAMMACK R, REMZI M, SEITZ C, DIAVAN B, MARBERGER M: Efficacy of oral doxepin and piroxicam treatment for interstitial cystitis. Eur. Urol. (2002) 41:596-600.
   PubMed Web of Science ®Google Scholar
• EPSTEIN JB, EPSTEIN JD, EPSTEIN MS, OIEN H, TRUELOVE EL: Oral doxepin rinse: the analgesic effect and duration of pain reduction in patients with oral mucositis due to cancer therapy. Anesth. Analg. (2006) 103:465-470.
   PubMed Web of Science ®Google Scholar
• GODFREY RG: A guide to the understanding and use of tricyclic antidepressants in the overall management of fibromyalgia and other chronic pain syndromes. Arch. Intern. Med. (1996) 27:1047-1052.
   Google Scholar
• SMITH KJ, SKELTON HG, YEAGER J, LEE RB, WAGNER KF: Pruritus in HIV-1 disease: therapy with drugs which may modulate the pattern of immune dysregulation. Dermatology (1997) 195:353-358.
   PubMed Web of Science ®Google Scholar
• SABROE RA, KENNEDY CT, ARCHER CB: The effects of topical doxepin on responses to histamine, substance P and prostaglandin E2 in human skin. Br. J. Dermatol. (1997) 137:386-390.
   PubMed Web of Science ®Google Scholar
• HOARE C, LI WAN PO A, WILLIAMS H: Systematic review of treatments for atopic eczema. Health Technol. Assess (2000) 4:1-191.
   PubMedGoogle Scholar
• BONNEL RA, LA GRENADE L, KARWOSKI CB, BEITZ JG: Allergic contact dermatitis from topical doxepin: food and drug administration's postmarketing surveillance experience. J. Am. Acad. Dermatol. (2003) 48:294-296.
   PubMed Web of Science ®Google Scholar
• ZELL-KANTER M, TOERNE TS, SPIEGEL K, NEGRUSZ A: Doxepin toxicity in a child following topical administration. Ann. Pharmacother. (2000) 34:328-329.
   PubMed Web of Science ®Google Scholar
• LEITOLD M, FLEISSIG W, MERK A: Anti-ulcer and secretion-inhibitory properties of the tricyclic derivative doxepin in rats and dogs. Rzneimittelforschung (1984) 34:468-473.
   PubMed Web of Science ®Google Scholar
• ANDERSON OK, BERGSAKER-ASPOY J, HALVORSEN L, GIERCKSKY KE: Doxepin in the treatment of duodenal ulcer. A double-blind clinical study comparing doxepin and placebo. Scand. J. Gastroenterol. (1984) 19:923-925.
   PubMed Web of Science ®Google Scholar
• WANG WA, OIAN JM, PAN GZ: Treatment of refractory irritable bowel syndrome with subclinical dosage of antidepressants. Zhongguo Yi Xue Ke Xue Yuan Xue Bao (2003) 25:74-78.
   PubMedGoogle Scholar
• PRAKASH C, LUSTMAN PJ, FREEDLAND KE, CLOUSE RE: Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig. Dis. Sci. (1998) 43:1951-1956.
   PubMed Web of Science ®Google Scholar
• PIES RW: Another case of doxepin for irritable bowel syndrome. Am. J. Psychiatry (1983) 140:368-369.
   PubMedGoogle Scholar
• GARTRELL N, MOSBACHER D: A case report of irritable bowel syndrome treated with doxepin. Am. J. Psychiatry (1982) 139:1351-1353.
   PubMed Web of Science ®Google Scholar
• JACKSON JL, O'MALLEY PG, TOMKINS G, BALDEN E, SANTORO J, KROENKE K: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. J. Med. (2000) 108:65-72.
   PubMed Web of Science ®Google Scholar
• BECKER PM: Insomnia: prevalence, impact, pathogenesis, differential diagnosis, and evaluation. Psychiatric Clin. North Am. (2006) 29:855-870.
   PubMed Web of Science ®Google Scholar
• BYELS JE, MISHRA GD, HARRIS MA: The experience of insomnia among older women. Sleep (2005) 28:972-979.
   PubMed Web of Science ®Google Scholar
• RAO V, SPIRO JR, SAMUS QM et al.: Sleep disturbances in the elderly residing in assisted living: findings from the Maryland Assisted Living Study. Int. J. Geriatr. Psychiatry (2005) 10:956-966.
   Google Scholar
• ANCOLI-ISRAEL S, AYALON L: Diagnosis and treatment of sleep disorders in older adults. Am. J. Geriatr. Psychiatry (2006) 2:95-103.
   Google Scholar
• RICHELSON E: Tricyclic antidepressants and histamine H1 receptors. Mayo Clin. Proc. (1979) 54:669-674.
   PubMed Web of Science ®Google Scholar
• GOONERATNE NS, GEHRMAN PR, NKWUO JE et al.: Consequences of comorbid insomnia symptoms and sleep-related breathing disorder in elderly subjects. Arch. Intern. Med. (2006) 166(16):1732-1738.
   PubMed Web of Science ®Google Scholar
• JI BS, JI H, LIU GQ: Doxepin protects cultured neurons against oxidative stress-induced injury. Acta Pharmacol. Sin. (2004) 3:297-300.
   Google Scholar
• CRAIG D, HART DJ, PASSMORE AP: Genetically increased risk of sleep disruption in Alzheimer's disease. Sleep (2006) 29:1003-1007.
   PubMed Web of Science ®Google Scholar

Websites

• http://en.wikipedia.org/wiki/Doxepin Article on doxepin. Wikipedia, the free encyclopedia (2007).
   Google Scholar
• http://somaxon.com/media/pdf/press2007/SOMX_preclinical_update_2-13-07.pdf Somaxon provides update on SILENOR™ preclinical program, press release (13 February 2007).
   Google Scholar
• http://somaxon.com/media/pdf/press2006/SOMX_Silenor_Adult_P3_News_Release_4-10-06.pdf Somaxon pharmaceuticals announces positive phase III results with SILENOR™ for the treatment of adults with chronic insomnia, press release (10 April 2006).
   Google Scholar
• http://somaxon.com/media/pdf/press2006/SOMX_509_Phase_3_Results_11-20-06.pdf Somaxon pharmaceuticals' SILENOR™ demonstrates positive results in its third Phase III clinical trial in insomnia, press release (20 November 2006).
   Google Scholar
• http://somaxon.com/media/pdf/press2006/SOMX_503_12-18-06.pdf Somaxon's SILENOR™ demonstrates positive results in long-term Phase III clinical trial in elderly patients with insomnia, press release (18 December 2006).
   Google Scholar